This loss of MHC-II expression is most commonly observed in the high-risk ABC-DLBCL subtype (8, 9) and R-CHOP treated DLBCL patients with reduced HLA-DRA expression exhibited significantly inferior survival (9). This evidence concerns the gene HLA-DRA and diffuse large B-cell lymphoma.